Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
02 2022
Historique:
received: 25 01 2021
accepted: 25 05 2021
pubmed: 7 7 2021
medline: 19 1 2022
entrez: 6 7 2021
Statut: ppublish

Résumé

An understanding of differences in clinical phenotypes and outcomes COVID-19 compared with other respiratory viral infections is important to optimise the management of patients and plan healthcare. Herein we sought to investigate such differences in patients positive for SARS-CoV-2 compared with influenza, respiratory syncytial virus (RSV) and other respiratory viruses. We performed a retrospective cohort study of hospitalised adults and children (≤15 years) who tested positive for SARS-CoV-2, influenza virus A/B, RSV, rhinovirus, enterovirus, parainfluenza viruses, metapneumovirus, seasonal coronaviruses, adenovirus or bocavirus in a respiratory sample at admission between 2011 and 2020. A total of 6321 adult (1721 SARS-CoV-2) and 6379 paediatric (101 SARS-CoV-2) healthcare episodes were included in the study. In adults, SARS-CoV-2 positivity was independently associated with younger age, male sex, overweight/obesity, diabetes and hypertension, tachypnoea as well as better haemodynamic measurements, white cell count, platelet count and creatinine values. Furthermore, SARS-CoV-2 was associated with higher 30-day mortality as compared with influenza (adjusted HR (aHR) 4.43, 95% CI 3.51 to 5.59), RSV (aHR 3.81, 95% CI 2.72 to 5.34) and other respiratory viruses (aHR 3.46, 95% CI 2.61 to 4.60), as well as higher 90-day mortality, ICU admission, ICU mortality and pulmonary embolism in adults. In children, patients with SARS-CoV-2 were older and had lower prevalence of chronic cardiac and respiratory diseases compared with other viruses. SARS-CoV-2 is associated with more severe outcomes compared with other respiratory viruses, and although associated with specific patient and clinical characteristics at admission, a substantial overlap precludes discrimination based on these characteristics.

Sections du résumé

BACKGROUND
An understanding of differences in clinical phenotypes and outcomes COVID-19 compared with other respiratory viral infections is important to optimise the management of patients and plan healthcare. Herein we sought to investigate such differences in patients positive for SARS-CoV-2 compared with influenza, respiratory syncytial virus (RSV) and other respiratory viruses.
METHODS
We performed a retrospective cohort study of hospitalised adults and children (≤15 years) who tested positive for SARS-CoV-2, influenza virus A/B, RSV, rhinovirus, enterovirus, parainfluenza viruses, metapneumovirus, seasonal coronaviruses, adenovirus or bocavirus in a respiratory sample at admission between 2011 and 2020.
RESULTS
A total of 6321 adult (1721 SARS-CoV-2) and 6379 paediatric (101 SARS-CoV-2) healthcare episodes were included in the study. In adults, SARS-CoV-2 positivity was independently associated with younger age, male sex, overweight/obesity, diabetes and hypertension, tachypnoea as well as better haemodynamic measurements, white cell count, platelet count and creatinine values. Furthermore, SARS-CoV-2 was associated with higher 30-day mortality as compared with influenza (adjusted HR (aHR) 4.43, 95% CI 3.51 to 5.59), RSV (aHR 3.81, 95% CI 2.72 to 5.34) and other respiratory viruses (aHR 3.46, 95% CI 2.61 to 4.60), as well as higher 90-day mortality, ICU admission, ICU mortality and pulmonary embolism in adults. In children, patients with SARS-CoV-2 were older and had lower prevalence of chronic cardiac and respiratory diseases compared with other viruses.
CONCLUSIONS
SARS-CoV-2 is associated with more severe outcomes compared with other respiratory viruses, and although associated with specific patient and clinical characteristics at admission, a substantial overlap precludes discrimination based on these characteristics.

Identifiants

pubmed: 34226206
pii: thoraxjnl-2021-216949
doi: 10.1136/thoraxjnl-2021-216949
pmc: PMC8260304
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154-163

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Pontus Hedberg (P)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden Pontus.hedberg@ki.se.
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

John Karlsson Valik (J)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Suzanne van der Werff (S)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Hideyuki Tanushi (H)

Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Ana Requena Mendez (A)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Fredrik Granath (F)

Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Max Bell (M)

Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.

Johan Mårtensson (J)

Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.

Robert Dyrdak (R)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.

Olof Hertting (O)

Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
Department of Paediatric Infectious Diseases, Astrid Lindgren's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Anna Färnert (A)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Anders Ternhag (A)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Pontus Naucler (P)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH